Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 4/20 | 0.40 |
| ▸ | RXRB | P28702 | 4/20 | 0.40 |
| ▸ | RXRG | P48443 | 4/20 | 0.40 |
| ▸ | POLQ | O75417 | 5/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6864256 | 0.77 | CES2 (0.41) | CES2GPR17RXRARXRBRXRG | |
| SCHEMBL6863880 | 0.76 | RXRA (0.33) | CES2RXRARXRBRXRG | |
| SCHEMBL21490263 | 0.76 | CES2 (0.41) | CES2GPR17RXRARXRBRXRG | |
| SCHEMBL18243397 | 0.76 | CES2 (0.41) | CES2GPR17EGLN1CACNA1H | |
| SCHEMBL6862955 | 0.75 | RXRA (0.35) | CES2RXRARXRBRXRG | |
| SCHEMBL6193603 | 0.75 | POLQ (0.58) | CES2RXRARXRBRXRGPOLQ | |
| SCHEMBL29315902 | 0.74 | RXRA (0.44) | CES2GPR17RXRARXRBRXRG | |
| SCHEMBL6865708 | 0.74 | CES2 (0.52) | CES2RXRARXRBRXRGLMNA | |
| SCHEMBL18242579 | 0.72 | GPR17 (0.39) | CES2GPR17RXRARXRBRXRG | |
| SCHEMBL20560309 | 0.71 | CES2 (0.36) | CES2GPR17GPR35CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797842-B2 | BY ASYMMETRICALLY REDUCING AN OPTICALLY ACTIVE IMINE, USING A HYDRIDE REDUCING AGENT TO CONVERT TO AN OPTICALLY ACTIVE SECONDARY AMINE, WHICH THEN UNDERGOES HYDROGENOLYSIS; HIGH OPTICAL PURITY, SIMPLE, EFFICIENT | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | MAP2K5, MAP2K4, MAP2K1 | CES2 2291/4885GPR17 4870/4885RXRA 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.